Ipilimumab

When it comes to naming children — at least in my generation — it was pretty straightforward.

The combination of ipilimumab and nivolumab extended PFS compared with ipilimumab alone as second-line therapy for patients with advanced melanoma resistant to PD-1 inhibitors, according to study results published in Nature Medicine.

The addition of nivolumab to cisplatin-based chemotherapy improved outcomes compared with standard regimens for certain patients with advanced urothelial carcinoma, according to the agent’s manufacturer.

CHICAGO — Tumor lymph node dissection likely can be omitted for patients with melanoma who achieve major pathologic response after neoadjuvant immune checkpoint blockade, according to study results presented at ASCO Annual Meeting.

SAN FRANCISCO — Healio spoke with Moshe Ornstein, MD, about the COSMIC-313 trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Moshe Ornstein, MD, spoke with Healio about a trial of intermittent therapy in patients with metastatic renal cell carcinoma presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, who was the senior author, discusses an analysis of COSMIC-313 presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Meredith M. Regan, ScD, discusses a study she presented at the annual ASCO Genitourinary Cancers Symposium that assessed treatment-free survival outcomes among patients with advanced clear cell renal cell carcinoma.

High BMI appeared associated with increased risk for any-grade immune-related adverse events among a cohort of patients with advanced cancer undergoing treatment with immune checkpoint inhibitors.

In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed important research on immunotherapy combinations presented at American Thyroid Association Annual Meeting.